NCT05963958

HD-Tdcs and Pharmacological Intervention For Delirium In Critical Patients With COVID-19

HD-Tdcs Associated With The Use Of Dexmedetomidine For Delirium In Critical Patients With Covid-19

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Suellen Andrade · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial Is conducted to evaluate the efficacy and safety of active or sham HD-tDCS in combination with dexmedetomidine in patients with moderate to severe ARDS due to COVID-19 with delirium in intensive care unit (ICU). The hypothesis was that HD-tDCS combined with concomitant dexmedetomidine would reduce delirium rates.

Conditions

• COVID-19
• Delirium
• Critical Illness

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Active HD-tDCS	Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
COMBINATION_PRODUCT	Sham HD-tDCS	Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19

Timeline

• Start date: 2021-04-14
• Primary completion: 2022-12-02
• Completion: 2023-01-30
• First posted: 2023-07-27
• Last updated: 2023-07-27

Locations

1 site across 1 country: Brazil